ADDERALL XR 10
LOE Approachingdextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Oct 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Adderall XR 10 is an extended-release oral capsule containing a combination of dextroamphetamine and amphetamine salts, approved in 2001. It is a CNS stimulant indicated for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The drug works by increasing the release of norepinephrine and dopamine in the brain, improving focus, attention, and wakefulness.
LOE Approaching
Brand approaching loss of exclusivity with 30% competitive pressure; expect transition from growth to defensive strategies and potential headcount reallocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Adderall XR offers exposure to a legacy franchise with deep market penetration but limited growth upside; career development is best suited for professionals seeking to master defensive brand management, generic competition strategies, and lifecycle extension. Takeda's portfolio role in stimulant ADHD therapy provides stability but requires strategic thinking on market erosion mitigation.
Brand Manager
Worked on ADDERALL XR 10 at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.